J. Bradley White

• AstraZeneca Canada Inc. et al. v Mylan Pharmaceuticals ULC et al. T-336-15 (2017), T-184-19
• Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1161-13 (2015) FC 751
• Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1451-11 (2015)
• Amgen Canada Inc. v Mylan Pharmaceuticals ULC et al. T-2056-14 (2015)
• Amgen Canada Inc. v. Mylan Pharmaceuticals ULC et al T-1584-17
• (Federal Court File No. T-1584-17) SENSIPAR (Cinacalcet) Section 8 Damages
• Novartis Pharmaceuticals v Mylan Pharmaceuticals ULC et al. T-365-14 (2014)
• AstraZeneca et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 312, 2012 FCA 109
• Pfizer Canada Inc et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 547; 2012 FCA 103
• Janssen Inc. v Mylan Pharmaceuticals ULC et al. T-1577-14 (2011)
• Sanofi-Aventis v Mylan Pharmaceuticals ULC et al. T-1441-12 (2010)
• Lundbeck Canada Inc. v Mylan Pharmaceuticals ULC et al. (2009) 73 C.P.R. (4th) 69 (F.C.T.D.); (2010) 88 C.P.R. (4th) 325 (F.C.A.), SCC 34068

Teva Canada Limited:

• Lead outside counsel to Teva Canada Limited in patent litigation, prosecution and other matters. Presently representing or successfully settled complex pharmaceutical and general litigation matters on behalf of Teva including in relation to CUBICIN® (Daptomycin), SPRYCEL® (Dasatinib Monohydrate) and VICTOZA® (Liraglutide).
• Bristol-Myers Squibb Canada Co v. Teva Canada Limited T-1774-18
• Bayer Inc. and Bayer Intellectual Property GMBH v. Teva Canada Limited T-1960-18, T-1021-19.
• Bayer Inc. et al v. Teva Canada Limited T-1692-18
• Novo Nordisk Canada Inc. v. Teva Canada Ltd. et al. T-727-18, T-65-19

Teva/Celltrion Healthcare:

• Lead outside counsel to Teva/Celltrion in complex pharmaceutical litigation matters including the biosimilars to RITUXAN® (Rituximab) and HERCEPTIN® (Trastuzumab).
• F. Hoffmann-La Roche Limited v. Celltrion et al. T-1486-17, T-1487-17, T-1488-17, T-1489-17
• Genentech, Inc. et al. v. Celltrion Healthcare Co., Ltd. T-1969-17, T-1970-17, T-1971-17

Samsung Bioepis:

• Representing Samsung Bioepis in several significant patent litigation cases, including the first case brought in Canada under the Patented Medicines (Notice of Compliance) Regulations in relation to blockbuster biopharmaceutical ENBREL® (etanercept). Also represented Samsung in patent litigation proceedings relation to the world’s biggest drug HUMIRA® (adalimumab).
• Abbvie Biotechnology et al v. Samsung Bioepis Co., Ltd. and the Minister of Health T-598-17, T-599-17, T-600-17, T-601-17, T-602-17, T-603-17, T-604-17, T-605-17
• Amgen Canada Inc. and Immunex Corporation v. Samsung Bioepis Co., Ltd. and the Minister of Health T-1283-15 (2014)

Standard Innovation Corporation:

• Representing Standard Innovation Corporation (now WOW Tech) in the role of world-wide coordinating litigation and IP counsel, including the following cases:
• Opposition Proceedings in respect of European Patent No. EP 1 824 440 in the European Patent Office
• Appeal from the US International Trade Commission, Investigation No. 337-TA-823, United States Court of Appeals for the Federal Circuit, No. 2013-1582, Lelo Inc. & Leloi AB v. International Trade Commission and Standard Innovation (US) Corp. & Standard Innovation Corporation
• District Court Action before the United States District Court of Northern California  5:13-cv-01393-PSG: Lelo Inc v. Standard Innovation (US) Corp and Standard Innovation Corporation
• Ex Parte reexamination of the United States Patent No. 7,931,605 (“the ‘605 Patent”)
• Lead Canadian IP  counsel to Standard Innovation Corporation including in T-925-12: Standard Innovation Corporation  v. Lelo AB et Lelo Inc., 1531011 Ontario Inc., Cana International Distributing Inc., Landco Import International Inc. and TBMBM Inc.
• Two Inter Partes Review Re: Standard Innovation Corporation (Petitioner) v. Lelo Inc. [Patent Owner; Cases IPR 2014-00148 and IPR 2014-00907, Re: United States Patent No. 7,749,178 (“the ‘178 Patent”)].

ratiopharm Inc:

• Abbott Laboratories v. ratiopharm Inc. et al. (2004), 31 C.P.R. (4^th) 321 (F.C.A.)
• Abbott Laboratories v. ratiopharm Inc. et al. (2005), 42 C.P.R. (4^th) 20 and 121 (F.C.T.D.)
• Abbott Laboratories v. ratiopharm Inc. et al. (2005) 34 C.P.R. (4^th) 468 (F.C.T.D.)

Novopharm Ltd:

• Janssen-Ortho Inc. and Daiichi Pharmaceutical Co, Ltd. v. Novopharm Ltd. et al. 2006 FC 1333, (2006) 57 C.P.R. (4^th) 6 and 58 (F.C.T.D.)
• Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 39 C.P.R. (4^th) 197 (F.C.A.)
• Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 35 C.P.R (4^th) 353 (F.C.T.D.), appeal dismissed (2005), 40 C.P.R. (4^TH) 1 (F.C.A.)

Other:

• Acting as counsel to Munchkin Baby Canada, Ltd. and its U.S. affiliate in the defence of a Federal Court patent infringement action relating to the defendants’ making and selling of cartridges for diaper pails. Angelcare Development Inc. et al. v. Munchkin, Inc et al  T-151-16
• Counsel to Skretting Canada Inc. in letters rogatory proceedings relating a US patent dispute concerning methods for raising fish. Marical, Inc. v. Skretting Canada Inc. SJM-51-2016
• Nycomed v. Genpharm ULC et al. 2008 FC 330, (2008), 64 C.P.R. (4^th) 388 (F.C.T.D.)